Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silexion Therapeutics Corp - Ordinary Shares (NQ:SLXN)

2.771 -0.019 (-0.69%)
Streaming Delayed Price Updated: 9:37 AM EST, Nov 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silexion Therapeutics Corp - Ordinary Shares

< Previous 1 2 3 4 Next >
Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session.
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday?
Silexion Therapeutics shares preclinical data on SIL-204, highlighting tumor reduction in KRAS-driven cancers and sustained drug efficacy for 56+ days. 
Via Benzinga
Check out the stocks that are attracting the most attention and driving market activity.
Let's dive into the action on the US markets on Tuesday. Here are the most active stocks that are driving the market today. 
Via Chartmill
Gold Gains 1%; Boeing Shares Rise Following Q4 Results
 
Via Benzinga
These stocks are moving in today's session
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results
 
Via Benzinga
The market is filled with gapping stocks in Tuesday's session.
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials planned for 2026. 
Via Benzinga
PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments
From PESG
Via Business Wire
Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures
Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56. 
Via Stocktwits
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises
From PESG Research
Via Business Wire
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Agilent, Bath & Body Works And 3 Stocks To Watch Heading Into Monday
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
What's Going On With Silexion Therapeutics Shares Wednesday?
Silexion Therapeutics shares are moving higher on Wednesday after the company reported that Guangzhou Sino-Israel bio-industry investment fund holds a decent stake in the company. 
Via Benzinga
US Stocks Mostly Lower; Target Posts Downbeat Earnings
 
Via Benzinga
Ilan Hadar, CEO of Silexion Therapeutics Corp. (NASDAQ: SLXN), to Present at NobleCon20
Via Investor Brand Network
Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Significant advancements in clinical and preclinical programs targeting KRAS-driven cancers; company advancing pipeline with focus on challenging oncology indications. 
Via News Direct
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit 
Via News Direct
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.